-
公开(公告)号:US20180318327A1
公开(公告)日:2018-11-08
申请号:US16033690
申请日:2018-07-12
申请人: INSMED INCORPORATED
发明人: Lawrence T. BONI , Brian S. MILLER
IPC分类号: A61K31/7036 , A61K31/496 , A61K9/00 , A61K31/407 , A61K9/127 , A61K31/545
CPC分类号: A61K31/7036 , A61K9/0073 , A61K9/0078 , A61K9/127 , A61K31/407 , A61K31/496 , A61K31/545 , A61P31/00 , Y02A50/406 , Y02A50/473 , Y10S977/773 , Y10S977/906 , Y10S977/907
摘要: Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.
-
公开(公告)号:US20180296484A1
公开(公告)日:2018-10-18
申请号:US15768352
申请日:2016-10-15
发明人: Daryl C. Drummond , Dmitri B. Kirpotin , Mark Eamon Hayes , Charles Noble , Kevin Kesper , Antoine M. Awad , Douglas J. Moore , Andrew J. O'Brien
IPC分类号: A61K9/127 , A61K31/4745
CPC分类号: A61K9/1271 , A61K9/1277 , A61K31/4745 , Y10S977/773 , Y10S977/906 , Y10S977/907
摘要: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.
-
公开(公告)号:US20180235954A1
公开(公告)日:2018-08-23
申请号:US15896436
申请日:2018-02-14
申请人: lpsen Biopharm Ltd.
发明人: Keelung Hong , Daryl C. Drummond , Dmitri Kirpotin
IPC分类号: A61K31/4745 , A61K9/00 , A61K47/69 , A61K9/127 , A61K47/26 , A61K47/24 , A61K31/4375 , A61K31/475 , A61K47/28 , A61K31/337 , A61K47/60 , A61K47/10 , A61K31/704 , C07H13/12
CPC分类号: A61K31/4745 , A61K9/0019 , A61K9/127 , A61K9/1271 , A61K9/1277 , A61K9/1278 , A61K31/337 , A61K31/4375 , A61K31/475 , A61K31/704 , A61K47/10 , A61K47/24 , A61K47/26 , A61K47/28 , A61K47/60 , A61K47/6913 , C07H13/12 , Y10S977/773 , Y10S977/906 , Y10S977/907
摘要: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.
-
公开(公告)号:US20180235894A1
公开(公告)日:2018-08-23
申请号:US15752008
申请日:2016-08-12
发明人: Zhen GU , Quanyin HU
CPC分类号: A61K9/5068 , A61K9/0019 , A61K31/337 , A61K31/351 , A61K31/437 , A61K31/4745 , A61K31/505 , A61K31/513 , A61K33/24 , A61K45/06 , A61K47/6803 , A61K2300/00 , A61P35/00 , Y10S977/773 , Y10S977/906
摘要: Disclosed herein is a platelet membrane-coated nanovehicle having an inner core comprising a drug delivery matrix, and an outer shell platelet membrane coating the inner core. The inner core can be any drug delivery matrix capable of delivering a therapeutic agent to a cell. The outer shell platelet membrane can be a natural or synthetic membrane comprising platelet proteins capable of interacting with cancer cells. Also disclosed is a method for treating cancer in a subject that involves administering to the subject a platelet membrane-coated nanovehicle disclosed herein. Also disclosed is a method for treating vascular disease in a subject that involves administering to the subject a platelet membrane-coated nanovehicle disclosed herein.
-
公开(公告)号:US20180200187A1
公开(公告)日:2018-07-19
申请号:US15920923
申请日:2018-03-14
IPC分类号: A61K9/127 , A61K31/485 , A61K31/4706 , A61K31/65
CPC分类号: A61K9/1278 , A61K9/127 , A61K31/4706 , A61K31/485 , A61K31/65 , Y10S977/773 , Y10S977/906 , Y10S977/907
摘要: Provided herein is technology relating to incorporation of drugs into liposomes and particularly, but not exclusively, to methods for incorporating drugs into liposomes using a weak base and related compositions.
-
公开(公告)号:US09980886B2
公开(公告)日:2018-05-29
申请号:US15149675
申请日:2016-05-09
IPC分类号: A61Q19/00 , A61K8/04 , A01N55/00 , A61K8/49 , A61Q9/02 , A61Q13/00 , A01N31/08 , A61K8/891 , A01N25/04 , A61K8/25 , A61K8/34 , A61K8/73 , A61Q17/00 , A61K8/81 , A61Q19/10 , A61K8/02 , A01N65/08 , A61K8/92
CPC分类号: A61K8/04 , A01N25/04 , A01N31/08 , A01N55/00 , A01N65/08 , A61K8/0212 , A61K8/0241 , A61K8/042 , A61K8/25 , A61K8/345 , A61K8/4946 , A61K8/73 , A61K8/8152 , A61K8/891 , A61K8/922 , A61K2800/244 , A61K2800/28 , A61K2800/33 , A61K2800/413 , A61K2800/48 , A61Q9/02 , A61Q13/00 , A61Q17/005 , A61Q19/00 , A61Q19/007 , A61Q19/10 , Y10S977/773 , Y10S977/906
摘要: A composition is provided to apply to the skin, hair, or external mucosa of a human or animal, and a method for using the composition. The composition includes for example a composition for application to skin, hair or external mucosa comprising: a) dispersed submicron particles of hydrophobic agent(s) having average particle size from 100 nm to 999 nm; b) an aqueous-solvent fluid; and c) rheological modifying agent(s); wherein the aqueous-solvent fluid is 10% to 95% wt. of one or more water miscible solvent(s), 4.99% to 89.99% wt. water, and 0.01% to 10% wt. of the rheological modifying agent(s); and wherein the hydrophobic agents comprise 0.01 to 70% wt. of the skin, hair or mucosal composition; and wherein the composition is substantially surfactant-free.
-
公开(公告)号:US20180133155A1
公开(公告)日:2018-05-17
申请号:US15576190
申请日:2016-05-23
申请人: Aphios Corporation
IPC分类号: A61K9/127 , A61P31/12 , A61K31/365 , A61K31/19 , A61K31/325 , A61K38/15 , A61K31/4045
CPC分类号: A61K9/1271 , A61K31/167 , A61K31/19 , A61K31/20 , A61K31/325 , A61K31/365 , A61K31/4045 , A61K38/15 , A61K47/6851 , A61K47/6913 , A61P31/12 , Y10S977/773 , Y10S977/906 , Y10S977/907 , A61K2300/00
摘要: Embodiments of the present invention are directed to particles having a Bryoid and a HDAC inhibitor for the treatment of latent viral disease.
-
8.
公开(公告)号:US20180125978A1
公开(公告)日:2018-05-10
申请号:US15625764
申请日:2017-06-16
申请人: Lipocine Inc.
发明人: Mahesh V. Patel
IPC分类号: A61K47/14 , A61K9/16 , A61K31/7048 , A61K31/568 , A61K31/5513 , A61K31/5383 , A61K31/496 , A61K31/4709 , A61K31/352 , B82Y5/00
CPC分类号: A61K47/14 , A61K9/1617 , A61K9/1676 , A61K9/4858 , A61K9/5015 , A61K9/5026 , A61K9/5078 , A61K9/5084 , A61K31/352 , A61K31/4709 , A61K31/496 , A61K31/5383 , A61K31/5513 , A61K31/568 , A61K31/7048 , A61K47/10 , B82Y5/00 , Y02A50/463 , Y10S977/906 , Y10S977/927
摘要: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation cost on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.
-
公开(公告)号:US09888691B2
公开(公告)日:2018-02-13
申请号:US14546038
申请日:2014-11-18
申请人: Avent, Inc.
IPC分类号: C23C18/44 , C23C18/16 , C08J7/04 , A01N59/16 , A61L29/10 , A61L27/30 , A61L15/18 , A01N25/34 , A61L29/16 , A61K33/38 , A61L15/46 , D06M11/83 , D06M16/00 , D06M23/08 , A61L15/42 , A61L27/54
CPC分类号: A01N59/16 , A01N25/34 , A61K33/38 , A61L15/18 , A61L15/42 , A61L15/46 , A61L27/306 , A61L27/54 , A61L29/106 , A61L29/16 , A61L2300/104 , A61L2300/404 , A61L2300/624 , A61L2400/12 , C08J7/04 , C08J2323/12 , C08J2327/06 , C08J2327/18 , C08J2375/04 , C08J2377/02 , C23C18/1637 , C23C18/1639 , C23C18/1641 , C23C18/1646 , C23C18/1689 , C23C18/44 , D06M11/83 , D06M16/00 , D06M23/08 , Y10S977/906 , A01N25/02 , A01N25/10 , A01N25/22 , A01N25/30 , A01N2300/00 , A01N37/06 , A01N43/50 , A01N43/80
摘要: The present invention comprises methods and compositions for antimicrobial silver compositions comprising silver nanoparticles. The present invention further comprises compositions for preparing silver nanoparticles comprising at least one stabilizing agent, one or more silver compounds, at least one reducing agent and a solvent. In one aspect, the stabilizing agent comprises a surfactant or a polymer. The polymer may comprise polymers such as polyacrylamides, polyurethanes, and polyamides. In one aspect, the silver compound comprises a salt comprising a silver cation and an anion. The anion may comprise saccharinate derivatives, long chain fatty acids, and alkyl dicarboxylates. The methods of the present invention comprise treating devices with the silver nanoparticle compositions, including, but not limited to, such devices as woven wound care materials, catheters, patient care devices, and collagen matrices. The present invention further comprises treatment of humans and animals wacr6ith the antimicrobial devices described herein.
-
公开(公告)号:US20170354732A1
公开(公告)日:2017-12-14
申请号:US15688053
申请日:2017-08-28
IPC分类号: A61K41/00 , A61K31/165 , A61K31/23 , A61K47/69 , A61K31/231 , A61K31/7034 , A61K9/51 , A61K9/00 , A61K9/50 , A61K31/357 , A61K47/02
CPC分类号: A61K41/00 , A61K9/0019 , A61K9/0053 , A61K9/5031 , A61K9/5094 , A61K9/5153 , A61K31/165 , A61K31/23 , A61K31/231 , A61K31/357 , A61K31/7034 , A61K41/0052 , A61K47/02 , A61K47/6941 , Y10S977/773 , Y10S977/906
摘要: A magnetic nanoparticle including a TRPV1 agonist, as well as methods of preparation and use, are described herein. A magnetically responsive pharmaceutical can include a core region having a magnetic nanoparticle (MNPs) and a TRPV1 protein agonist. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field.
-
-
-
-
-
-
-
-
-